Bibliometric analysis of immunotherapy for esophageal cancer: 2004-2024

食管癌免疫疗法的文献计量分析:2004-2024

阅读:1

Abstract

Esophageal cancer (EC) remains one of the most lethal malignancies worldwide, with particularly high incidence and mortality rates in developing countries. In recent years, immunotherapy has emerged as a promising treatment strategy. This study employed bibliometric visualization tools, including CiteSpace and VOSviewer, to analyze research pertaining to immunotherapy in esophageal cancer. Based on 780 English-language publications indexed in the Web of Science database from 2004 to 2024, we quantitatively examined the research landscape, evolutionary trends, and knowledge structure of this field. The results indicated a steady increase in annual publications, with China being the leading contributor and Zhengzhou University as the most productive institution. Frontiers in Oncology and Journal of Clinical Oncology were the most prolific and most co-cited journals, respectively, while Kato Ken and Kojima Takashi were identified as the most influential scholars in the field. The research focus has shifted from traditional radiotherapy and chemotherapy to immunotherapy-related areas, such as the tumor immune microenvironment, immune checkpoint inhibitors, PD-L1 expression, and microsatellite instability. Current research emphasizes combining immunotherapy with other modalities, including radiotherapy, chemotherapy, and targeted therapy, pointing toward future multimodal combination strategies. Additionally, efforts are directed at identifying novel biomarkers to enhance treatment efficacy, reduce toxicity, and improve patient survival.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。